Brief: Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults
09/11/2023 13:48
Nov 9 (Reuters) - Vaxcyte Inc PCVX.O :
* VAXCYTE DOSES FIRST PARTICIPANTS IN PHASE 1/2 CLINICAL
STUDY
EVALUATING VAX-31 FOR THE PREVENTION OF INVASIVE PNEUMOCOCCAL
DISEASE IN ADULTS
* VAXCYTE INC - TOPLINE SAFETY, TOLERABILITY AND
IMMUNOGENICITY
DATA EXPECTED IN SECOND HALF OF 2024
Source text for Eikon: ID:nGNX3K3jXn
Further company coverage: PCVX.O
((Reuters.Briefs@thomsonreuters.com;))